Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Oral Peanut Desensitization
NCT01781637Phase 2Completed
- Sponsor
- Boston Children's Hospital
- Start
- Jan 2013
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in peanut allergy, sponsored by Boston Children's Hospital. Started Jan 2013; status: completed.
02
Drugs
omalizumab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT01781637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01781637.